- Home
- AKAN vs QLGN Comparison
AKAN vs QLGN Comparison
Compare AKAN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- QLGN
- Stock Information
- Founded
- AKAN 2021
- QLGN 1996
- Country
- AKAN Canada
- QLGN United States
- Employees
- AKAN N/A
- QLGN N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- AKAN Health Care
- QLGN Health Care
- Exchange
- AKAN Nasdaq
- QLGN Nasdaq
- Market Cap
- AKAN 2.9M
- QLGN 3.1M
- IPO Year
- AKAN 2022
- QLGN N/A
- Fundamental
- Price
- AKAN $3.33
- QLGN $2.03
- Analyst Decision
- AKAN
- QLGN
- Analyst Count
- AKAN 0
- QLGN 0
- Target Price
- AKAN N/A
- QLGN N/A
- AVG Volume (30 Days)
- AKAN 158.8K
- QLGN 43.8K
- Earning Date
- AKAN 10-29-2025
- QLGN 11-13-2025
- Dividend Yield
- AKAN N/A
- QLGN N/A
- EPS Growth
- AKAN N/A
- QLGN N/A
- EPS
- AKAN N/A
- QLGN N/A
- Revenue
- AKAN $836,664.00
- QLGN N/A
- Revenue This Year
- AKAN N/A
- QLGN N/A
- Revenue Next Year
- AKAN N/A
- QLGN N/A
- P/E Ratio
- AKAN N/A
- QLGN N/A
- Revenue Growth
- AKAN 97.47
- QLGN N/A
- 52 Week Low
- AKAN $2.91
- QLGN $1.61
- 52 Week High
- AKAN $8.75
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- AKAN 41.55
- QLGN 52.80
- Support Level
- AKAN $3.14
- QLGN $1.66
- Resistance Level
- AKAN $3.68
- QLGN $2.16
- Average True Range (ATR)
- AKAN 0.37
- QLGN 0.11
- MACD
- AKAN -0.03
- QLGN 0.08
- Stochastic Oscillator
- AKAN 15.20
- QLGN 74.15
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.